Mirum Pharmaceuticals Agrees to $68.5 Million Equity Private Placement

MT Newswires Live

12/19

Mirum Pharmaceuticals (MIRM) said Friday it has entered into a subscription agreement with institutional investor TCGX for a private placement of 1 million shares priced at $68.48 each, for about $68.5 million in gross proceeds.

The company said it will use the proceeds, along with a $200 million private placement agreed to earlier this month, to fund clinical development and commercial activities after its proposed acquisition of Bluejay Therapeutics.

The private placements are expected to close at the same time as the anticipated Q1 2026 acquisition, the company said.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2592160257"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2592160257\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2592160257?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-19 22:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592160257","market":"sg","top_or_hot":-1,"title":"Mirum Pharmaceuticals Agrees to $68.5 Million Equity Private Placement","media":"MT Newswires Live","content":"<html><body><p> Mirum Pharmaceuticals (MIRM) said Friday it has entered into a subscription agreement with institutional investor TCGX for a private placement of 1 million shares priced at $68.48 each, for about $68.5 million in gross proceeds.</p><p>The company said it will use the proceeds, along with a $200 million private placement agreed to earlier this month, to fund clinical development and commercial activities after its proposed acquisition of Bluejay <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>.</p><p>The private placements are expected to close at the same time as the anticipated Q1 2026 acquisition, the company said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mirum Pharmaceuticals Agrees to $68.5 Million Equity Private Placement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMirum Pharmaceuticals Agrees to $68.5 Million Equity Private Placement\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-12-19 22:09</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Mirum Pharmaceuticals (MIRM) said Friday it has entered into a subscription agreement with institutional investor TCGX for a private placement of 1 million shares priced at $68.48 each, for about $68.5 million in gross proceeds.</p><p>The company said it will use the proceeds, along with a $200 million private placement agreed to earlier this month, to fund clinical development and commercial activities after its proposed acquisition of Bluejay <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>.</p><p>The private placements are expected to close at the same time as the anticipated Q1 2026 acquisition, the company said.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MIRM","symbol_name":"Mirum Pharmaceuticals, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2592160257","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592160257","pubTimestamp":1766153356,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mirum Pharmaceuticals  said Friday it has entered into a subscription agreement with institutional investor TCGX for a private placement of 1 million shares priced at $68.48 each, for about $68.5 million in gross proceeds.The company said it will use the proceeds, along with a $200 million private placement agreed to earlier this month, to fund clinical development and commercial activities after its proposed acquisition of Bluejay Therapeutics.The private placements are expected to close at the same time as the anticipated Q1 2026 acquisition, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MIRM":"Mirum Pharmaceuticals, Inc.","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","EQR":"资产住宅公司","BK4215":"住宅房地产投资信托"},"translate_title":"Mirum Pharmaceuticals同意进行6850万美元的股权私募","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EQR":1.5,"MIRM":1},"content_text":"Mirum Pharmaceuticals (MIRM) said Friday it has entered into a subscription agreement with institutional investor TCGX for a private placement of 1 million shares priced at $68.48 each, for about $68.5 million in gross proceeds.The company said it will use the proceeds, along with a $200 million private placement agreed to earlier this month, to fund clinical development and commercial activities after its proposed acquisition of Bluejay Therapeutics.The private placements are expected to close at the same time as the anticipated Q1 2026 acquisition, the company said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}